Bcl-2/Bcl-xL dual inhibitor
Showing 1 - 25 of >10,000
Laryngeal Cancer Trial in Ann Arbor (AT-101, Docetaxel, Cisplatin)
Completed
- Laryngeal Cancer
- AT-101
- +3 more
-
Ann Arbor, MichiganUniversity of Michigan Comprehensive Cancer Center
Dec 17, 2021
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial (BGB-21447)
Not yet recruiting
- Relapsed Non-Hodgkin Lymphoma
- +6 more
- (no location specified)
Apr 12, 2023
Acute Myeloid Leukemia, MDS, Chronic Myelomonocytic Leukemia Trial (LP-108, Azacitidine)
Not yet recruiting
- Acute Myeloid Leukemia
- +2 more
- (no location specified)
Nov 29, 2022
Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma Trial (Biopsy, Biospecimen
Not yet recruiting
- Metastatic Endometrial Carcinoma
- +7 more
- Biopsy
- +5 more
- (no location specified)
Jan 18, 2023
Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial in Boston
Active, not recruiting
- Metastatic Malignant Solid Neoplasm
- +2 more
- Biopsy
- +6 more
-
Boston, Massachusetts
- +1 more
Nov 8, 2022
Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory Trial
Not yet recruiting
- Waldenstrom Macroglobulinemia
- +2 more
- (no location specified)
Jul 18, 2023
Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia Trial in Columbus (drug, biological, other)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Refractory Chronic Lymphocytic Leukemia
- Bcl-2 Inhibitor GDC-0199
- +5 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Oct 29, 2021
Acute Myeloid Leukemia Trial in Beijing (Ven+CAG)
Recruiting
- Acute Myeloid Leukemia
-
Beijing, Beijing, ChinaPeking University People's Hospital
Jun 23, 2023
T-lymphoblastic Lymphoma, Relapsed Disease, Refractory Lymphoma Trial in Shanghai (BCL2 Inhibitor plus IM2 regimen)
Recruiting
- T-lymphoblastic Lymphoma
- +5 more
- BCL2 Inhibitor plus IM2 regimen
-
Shanghai, Shanghai, ChinaShanghai General hospital,Shanghai Jiao Tong University School o
Jan 10, 2023
Acute Myeloid Leukemia, Relapsed Cancer, Refractory Cancer Trial in Edmonton, Toronto (Enasidenib, Venetoclax)
Active, not recruiting
- Acute Myeloid Leukemia
- +3 more
-
Edmonton, Alberta, Canada
- +1 more
Jan 31, 2023
Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between
Not yet recruiting
- Recurrent ALK Positive Large B-Cell Lymphoma
- +28 more
- Biospecimen Collection
- +5 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Aug 17, 2022
Gut Microbiota in Acute Myeloid Leukemia Receiving Two Different
Not yet recruiting
- Acute Myeloid Leukemia
- +3 more
- collection of biological samples and clinical data
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University, Jiangsu Ins
Nov 5, 2021
Acute Myeloid Leukemia, MDS Trial in Hangzhou (Decitabine for Injection, VENCLYXTO)
Not yet recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Decitabine for Injection
- VENCLYXTO
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital, College of Medicine, Zhejiang Uni
Sep 18, 2023
Small Cell Lung Cancer and Other Solid Tumors Trial in Guangzhou (APG-1252)
Terminated
- Small Cell Lung Cancer and Other Solid Tumors
-
Guangzhou, Guangdong, ChinaGuangdong General Hospital
Aug 24, 2021
Refractory Soft Tissue Sarcomas Trial run by the NCI (Cabozantinib)
Active, not recruiting
- Refractory Soft Tissue Sarcomas
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Dec 5, 2022
Mature B-Cell Malignancies Trial in Worldwide (BGB-11417, Zanubrutinib)
Recruiting
- Mature B-Cell Malignancies
-
Stanford, California
- +26 more
Dec 16, 2021
Adult Acute Myeloid Leukemia Trial in Beijing (microtransplantation, HLA-mismatched donor peripheral stem cell infusion,
Recruiting
- Adult Acute Myeloid Leukemia
- microtransplantation, HLA-mismatched donor peripheral stem cell infusion
- +2 more
-
Beijing, Beijing, ChinaThe fifth medical center of PLA General Hospital
Feb 21, 2022
High Grade Serous Carcinoma, Triple Negative Breast Cancer, Ovarian Cancer Trial (Olaparib tablet, Navitoclax)
Recruiting
- High Grade Serous Carcinoma
- +2 more
- Olaparib tablet
- Navitoclax
-
Toronto, Ontario, Canada
- +2 more
Nov 28, 2022
Acute Myeloid Leukaemia Trial in Australia, France, United States (S 64315 (also referred as MIK665) and venetoclax)
Terminated
- Acute Myeloid Leukaemia
- S 64315 (also referred as MIK665) and venetoclax
-
New Haven, Connecticut
- +6 more
Dec 20, 2022
Multiple Myeloma Trial in Rochester (procedure, biological, drug)
Not yet recruiting
- Multiple Myeloma
- Biospecimen Collection
- +12 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Sep 15, 2023
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Recurrent B Acute
Recruiting
- B Acute Lymphoblastic Leukemia
- +2 more
- Dasatinib
- +4 more
-
Portland, OregonOHSU Knight Cancer Institute
Dec 16, 2022
Advanced Breast Cancer Trial in Changsha (TQB3909 tablets)
Recruiting
- Advanced Breast Cancer
- TQB3909 tablets
-
Changsha, Hunan, ChinaHunan Cancer Hospital
Mar 16, 2023